Sphingolipids and deoxysphingolipids in diabetes

Jonathan Schofield(University of Manchester), Handrean Soran(Manchester University NHS Foundation Trust), Tarza Siahmansur(University of Manchester), Irina Alecu(University of Zurich), Arnold von Eckardstein(University Hospital of Zurich), Thorsten Hornemann(University Hospital of Zurich), P. Pemberton(University of Manchester), R. Steiner(University Hospital Zurich), Sean Carroll(University of Hull), Shazli Azmi(University of Manchester), James Hobkirk(University of Hull), Y. Liu(University of Manchester), Donald Whitelaw(Bradford Teaching Hospitals NHS Foundation Trust)
Atherosclerosis
December 1, 2016
10.1016/j.atherosclerosis.2016.09.054
Cited by 1

Related Papers

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
|European Heart Journal|2022|1.3k
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
|European Heart Journal|2016|830
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
|New England Journal of Medicine|2019|663
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
|The Lancet Diabetes & Endocrinology|2018|340
High-Density Lipoproteins
|Circulation Journal|2013|179